## Teklab Gebregiworgis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3108526/publications.pdf

Version: 2024-02-01

20 papers 1,228 citations

687220 13 h-index 19 g-index

24 all docs

24 docs citations

times ranked

24

2352 citing authors

#	Article	IF	CITATIONS
1	MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell, 2017, 32, 71-87.e7.	7.7	373
2	MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13787-13792.	3.3	207
3	Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer & Metabolism, 2014, 2, 18.	2.4	182
4	Application of NMR Metabolomics to Search for Human Disease Biomarkers. Combinatorial Chemistry and High Throughput Screening, 2012, 15, 595-610.	0.6	116
5	Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. Nature Communications, 2019, 10, 224.	5.8	66
6	A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica. Journal of Proteome Research, 2016, 15, 659-666.	1.8	45
7	Glucose Limitation Alters Glutamine Metabolism in MUC1-Overexpressing Pancreatic Cancer Cells. Journal of Proteome Research, 2017, 16, 3536-3546.	1.8	27
8	Insights into gemcitabine resistance and the potential for therapeutic monitoring. Metabolomics, 2018, 14, 156.	1.4	25
9	Calmodulin disrupts plasma membrane localization of farnesylated KRAS4b by sequestering its lipid moiety. Science Signaling, 2020, 13, .	1.6	23
10	The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. Nature Communications, 2021, 12, 6274.	5.8	22
11	Oncogenic KRAS G12D mutation promotes dimerization through a second, phosphatidylserine–dependent interface: a model for KRAS oligomerization. Chemical Science, 2021, 12, 12827-12837.	3.7	19
12	Potential of Urinary Metabolites for Diagnosing Multiple Sclerosis. ACS Chemical Biology, 2013, 8, 684-690.	1.6	17
13	Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors. Journal of Thoracic Oncology, 2022, 17, 277-288.	0.5	11
14	Multiplexed Real-Time NMR GTPase Assay for Simultaneous Monitoring of Multiple Guanine Nucleotide Exchange Factor Activities from Human Cancer Cells and Organoids. Journal of the American Chemical Society, 2018, 140, 4473-4476.	6.6	9
15	NMR in integrated biophysical drug discovery for RAS: past, present, and future. Journal of Biomolecular NMR, 2020, 74, 531-554.	1.6	9
16	Regulation of GTPase function by autophosphorylation. Molecular Cell, 2022, 82, 950-968.e14.	4.5	9
17	Structures of RGL1 RAS-Association Domain in Complex with KRAS and the Oncogenic G12V Mutant. Journal of Molecular Biology, 2022, 434, 167527.	2.0	4
18	MO14-2 KRAS Q61H mutation evades the regulation of tyrosyl phosphorylation and renders cancer cells resistant to SHP2 inhibitor. Annals of Oncology, 2021, 32, S306.	0.6	0

#	Article	IF	CITATIONS
19	Abstract 5391: MUC1 and HIF-1α signaling interactions modulate glucose flux in pancreatic cancer , 2013, , .		o
20	Real-Time NMR. , 2019, , 1-10.		0